



## Caladrius Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

August 30, 2018

**BASKING RIDGE, N.J. (August 30, 2018)** – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present a corporate overview at the 20<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., on Wednesday, September 5 at 11:15 a.m. Eastern time. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

A live and archived webcast of Dr. Mazzo's presentation will be available under the events page in the investors section of the Company's website at [www.caladrius.com](http://www.caladrius.com).

### About Caladrius Biosciences

Caladrius is a clinical-stage biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. The Company's goal is to build a broad portfolio of novel and versatile products that address important unmet medical needs. Our current product candidates include two clinical-stage treatments for cardiovascular diseases based on our CD34 cell therapy platform: CLBS12, recipient of SAKIGAKE designation, in Phase 2 testing in Japan and eligible for early conditional approval for the treatment of critical limb ischemia; and CLBS14, in Phase 2 testing for the treatment of coronary microvascular dysfunction and in late-stage clinical development for refractory angina for which it has received RMAT designation. Caladrius' autoimmune product candidate in Phase 2 testing, CLBS03, is an *ex vivo* expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes. CLBS03 has been awarded Fast Track and Orphan designations by the FDA. For more information on the company, please visit [www.caladrius.com](http://www.caladrius.com).

### Contacts:

#### Investors:

Caladrius Biosciences, Inc.

John Menditto

Executive Director, Investor Relations and Corporate Communications

Phone: +1-908-842-0084

Email: [jmenditto@caladrius.com](mailto:jmenditto@caladrius.com)

#### LHA Investor Relations

Miriam Weber Miller

Senior Vice President

Phone: +1-212-838-3777

Email: [mmiller@lhai.com](mailto:mmiller@lhai.com)



Source: Caladrius Biosciences, Inc.